ACI Brasil

What ACI Brasil does

ACI Brasil is a Contract Research Organization (CRO) specialized in veterinary product development, headquartered in São Paulo, Brazil. Founded in 2023 as the Brazilian subsidiary of ACI Biosciences (a US-based CRO founded in 1998 by Dr. Chand Khanna, former U.S. National Cancer Institute Senior Investigator), the company offers three core service lines: multicentric clinical study execution, CMC (Chemistry, Manufacturing and Controls) services covering API development through process validation, and development planning and project management. Operations are underpinned by an internal Quality Management System aligned to ISO 9001:2015 and VICH GL9 Good Clinical Practice standards, with structured interaction with MAPA (the Brazilian agricultural regulator).

The company's clinical execution model relies on a pre-qualified network of veterinary clinics, hospitals, and universities across Brazil, supported by electronic data capture via Prelude or Medrio EDC platforms with audit trails, real-time monitoring, and edit checks. ACI Brasil is currently executing two active multicenter studies — a feline hypertension trial sponsored by CEVA Saude Animal and a canine osteoarthritis monoclonal antibody study — and plans a third trial on canine visceral leishmaniasis. Its "Studies Hub" platform connects sponsors, veterinary investigators, and pet families as part of a recruitment ecosystem, and a strategic partnership with CPABR extends its clinical and pre-clinical capabilities.

Revenue is generated through project-based professional services contracts with animal health companies developing veterinary pharmaceuticals and biologics for Brazilian and international registration; pet-owner participation in trials is free. Pricing is not publicly disclosed, and the company is privately held with no venture funding or revenue disclosed in public sources.

Name

ACI Brasil

Legal name

ACI Brasil

Website

https://aci-br.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Veterinary Contract Research Services

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Veterinary CRO services
• Multicentric clinical studies
• Veterinary product development
• CMC pharmaceutical services
• Clinical research organization

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Multicentric Clinical Study Services: ACI Brasil manages and executes clinical studies for animal health companies (sponsors) seeking regulatory approval for veterinary products in Brazil and international markets. Services include protocol development, study conduct, data management, and final study reports. Revenue is generated through project-based contracts with pharmaceutical and biotech companies.
2. CMC (Chemistry, Manufacturing and Controls) Services: Comprehensive CMC services covering drug substance (API) development, formulation, manufacturing process development, analytical method development and validation, regulatory support, and process validation. Can be provided as discrete services or integrated product development programs for veterinary pharmaceutical products.
3. Development Planning and Project Management Services: Strategic consulting services including development plan elaboration, project management, and scientific support. Helps sponsors structure veterinary product development from Target Product Profile through regulatory submissions, improving predictability of timelines, costs, governance, and decision-making.
4. Quality Assurance and Regulatory Services: Quality management system services, regulatory affairs support, and compliance consulting. Includes internal and external audits, CAPA management, and regulatory interactions with agencies like MAPA (Brazil).

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

ACI Brasil is a Contract Research Organization (CRO) that executes multicentric clinical studies in veterinary medicine and provides CMC (Chemistry, Manufacturing and Controls) services and development planning/project management for animal health sponsors. Services span protocol design, study conduct, data management, and final study reports across a pre-qualified network of veterinary clinics and hospitals in Brazil, supporting product registration with MAPA and international agencies. The offering is backed by an in-house Quality Management System aligned to ISO 9001:2015 and VICH GL9 Good Clinical Practices.

Product overview

ACI Brasil operates as a Contract Research Organization (CRO) offering an integrated suite of three core service lines — (1) Estudos Multicêntricos, (2) CMC – Chemistry, Manufacturing and Controls, and (3) Planos de Desenvolvimento, Gerenciamento de Projetos e Apoio Científico — all underpinned by its own Quality Management System (QMS) aligned to ISO 9001:2015 and VICH GL9 standards. The Estudios Multicêntricos service is the primary product, covering full-cycle multicenter clinical study execution (protocol design through final study report) across a pre-qualified network of veterinary clinics, hospitals, and universities, with electronic data capture via Prelude or Medrio EDC platforms. The Studies Hub serves as the public-facing platform connecting sponsors, veterinarians, and pet families, while two active clinical studies — Osteoartrite Canina (canine osteoarthritis monoclonal antibody) and Hipertensão Felina (feline hypertension, already approved in EU/US) — represent the company's live product offerings. ACI Brasil is a subsidiary of ACI Biosciences (USA), founded by Dr. Chand Khanna.

Differentiator

Problem solved

Functional benefit

Products and services

• Estudos Multicêntricos (Multicentric Clinical Studies) End-to-end execution of multicentric clinical studies for veterinary pharmaceutical and biological products, from protocol elaboration and study planning through data management and final study report, conducted via a pre-qualified Researcher Network of veterinary hospitals and clinics in Brazil, using electronic data capture systems and Good Clinical Practices (VICH GL9).
• CMC – Chemistry, Manufacturing and Controls Comprehensive CMC services covering API (drug substance) development, formulation and manufacturing process development, analytical development and validation, global regulatory support, and process validation across multiple pharmaceutical forms, animal species, and regulatory markets, for both new veterinary products and reformulation, reverse engineering, and line extension programs.
• Planos de Desenvolvimento, Gerenciamento de Projetos e Apoio Científico (Development Plans, Project Management, and Scientific Support) Strategic consulting for creating Development Plans that structure veterinary product development end-to-end, including Target Product Profile, regulatory strategy, study design, CMC, Gantt charts, costs, and risk registers, applying project management practices (sequencing, dependencies, critical path, risk mitigation, budget control) to improve predictability of timelines, costs, governance, and decision-making.
• Osteoartrite Canina — Monoclonal Antibody Clinical Study Multicentric clinical study evaluating an investigational monoclonal antibody for pain relief associated with canine osteoarthritis, conducted across ACI Brasil's partner clinics in Brazil with ~16 weeks of participation and 10 visits including clinical exams, radiographs, blood tests, and pain evaluation; pet participants receive complimentary activity monitors at study end.
• Hipertensão Felina — Feline Hypertension Clinical Study Multicentric clinical study evaluating a drug for feline hypertension already registered and commercialized in Europe and the United States, now under clinical evaluation for Brazil registration. Sponsored by CEVA Saude Animal, the study runs over ~4 weeks with 4 clinic visits.
• Studies Hub Central online hub that connects sponsors, local specialist veterinarians, and pet families to participate in ACI Brasil's multicentric clinical trials, presenting active studies, methodology, expertise areas, and pathways for sponsors, veterinarians, and pet families to engage.

Quantifiable outcome

• Studies conducted in compliance with VICH GL9 standards suitable for registration in Brazil and international markets
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• CPABR (Centro de Pesquisa Animal do Brasil)coreStrategic or Co-development PartnerCPABR is a key strategic partner for ACI Brasil in clinical research, described as a leader in clinical, pre-clinical, and scientific research in Brazil. Together they execute studies, share experiences and expertise, and drive animal health in Brazil. CPABR creates and enhances a network of veterinary specialists, investigative clinics, and other agents, elevates the quality of clinical studies in Brazil by combining international and national quality standards, and facilitates and consolidates clinical and pre-clinical study offerings for the Brazilian market.
• ACI Biosciences (Parent Company, USA)coreStrategic or Co-development PartnerACI Biosciences is the US-based parent company of ACI Brasil. Founded by Dr. Chand Khanna, an oncologist veterinary, PhD and former Senior Investigator at the U.S. National Cancer Institute, ACI Biosciences provides strategic support in regulatory affairs, product development, CMC, biologics, data management, and quality assurance. Led by Dr. Kristen Khanna as CEO, ACI Biosciences is an integrated veterinary product development company with broad scientific and regulatory support for multiple markets and countries.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Covance (Labcorp Drug Development): Covance/Labcorp is a global, broad life sciences CRO providing clinical development, central laboratory, and CMC services across human and animal health. It competes with ACI Brasil for any sponsor that prefers a full-service, multi-region provider rather than a Brazil-specialized vet CRO.
• Charles River Laboratories: Charles River is a large, diversified CRO and CDMO with preclinical, clinical, and manufacturing services used by pharma and animal health sponsors. As a broad incumbent, it overlaps with ACI Brasil on CMC and clinical study design for animal health clients.
• CEVA Santé Animale: CEVA is a top global animal health pharmaceutical company; it is also ACI Brasil's named sponsor for the Feline Hypertension study. Comparable as a customer-side peer for any sponsor operating in Brazilian veterinary registration.

Direct peers

• Vetio: Vetio is a contract development and manufacturing organization (CDMO) and research services provider dedicated to animal health, offering formulation, analytical, and clinical research support. It overlaps directly with ACI Brasil's CMC service line and clinical execution for veterinary sponsors.
• KRISH (Veterinary Contract Research): KRISH provides contract research services for animal health companies, including clinical trial design and execution, regulatory support, and consulting — directly mirroring ACI Brasil's core offer to veterinary sponsors.
• Triveritas: Triveritas is a veterinary-focused CRO offering multicenter clinical trial services, regulatory affairs, and pharmacovigilance for animal health companies across Europe and globally. Like ACI Brasil, it serves sponsors seeking registration-quality GCP/VICH-aligned data, making it the closest direct comparable.
• KLIFOVET: KLIFOVET is a veterinary CRO providing clinical trial management, regulatory affairs, and pharmacovigilance for animal health products. It is comparable to ACI Brasil in service portfolio, GCP/VICH focus, and sponsor base.
• Argenta (a Vimian Group company): Argenta is a global animal health CRO and CDMO providing clinical research, regulatory, and product development services. Its full-lifecycle animal health development model directly overlaps with ACI Brasil's integrated clinical + CMC + development planning offering.
• CPABR (Centro de Pesquisa Animal do Brasil): CPABR is ACI Brasil's strategic partner for preclinical and clinical research in Brazil — and simultaneously a peer, as it conducts veterinary studies and supports sponsor registrations in the Brazilian market alongside ACI Brasil.

Others

• IDEXX Livestock and Poultry / IDEXX Reference Laboratories: IDEXX provides veterinary diagnostics and reference laboratory services used within animal health product development and post-market surveillance. It is an adjacent enabling vendor to CROs like ACI Brasil rather than a direct trial executor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aci-biosciences-brasil

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACI Brasil